Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals Q3 revenue rises 23% to $342 million; raises DAYBUE guidance

Mixed Impact 4 of 5 earnings

Acadia reported third-quarter 2026 GAAP total revenues of $342 million, up 23% from a year earlier, with DAYBUE net sales up 39% to $140 million. Net income fell to $54 million, or $0.31 per diluted share, from $72 million, or $0.42, a year earlier. The company raised its 2026 DAYBUE net sales guidance and narrowed its total revenue range, while lowering its R&D expense guidance.

Key points

  • Q3 2026 GAAP total revenues were $342 million, up from $279 million in Q3 2025; NUPLAZID net sales were $202 million and DAYBUE net sales were $140 million.
  • Q3 2026 net income was $54 million, or $0.31 per diluted share, versus $72 million, or $0.42 per diluted share, in Q3 2025.
  • 2026 DAYBUE net sales guidance raised to $505 to $520 million from $480 to $510 million; total revenue guidance narrowed to $1.265 to $1.295 billion from $1.24 to $1.30 billion.
  • Cash, cash equivalents and investment securities were $976 million at September 30, 2026, up from $820 million at December 31, 2025.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:13 PM ET
Accession number0001193125-26-447276

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.